Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

X Leveraged ETFs for Rocket Lab and Hims & Hers ●RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment ...

Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.

Hims & Hers (NYSE: HIMS) is taking investors on a roller-coaster ride in 2025. Where to invest $1,000 right now? Our analyst ...

We recently compiled a list of the 10 Best Skincare Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...

Hims & Hers Health will shut down Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to “simplify its (company’s) dermatology ...

Former US Army Sgt. Mark Millich’s sex drive plummeted — and his genitals shrank and changed shape after taking popular hair-loss drug finasteride.